Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Neriifolin** is a plant-derived cardenolide (cardiac glycoside) found in species such as Cerbera odollam and Thevetia neriifolia, structurally related to the digitalis class of cardiac glycosides[1][4]. It inhibits the Na+/K+-ATPase (sodium-potassium pump), leading to increased intracellular calcium, causing positive inotropic effects in cardiac tissue (cardiotonic action), and can induce cell apoptosis[3][4][6]. Preclinical studies have shown anti-cancer activity through apoptosis in breast, ovarian, colorectal, and skin cancer lines and neuroprotective effects in models of ischemic stroke[3][4][6]. Neriifolin is considered a toxin due to its ability to induce cardiac arrhythmia and death in high doses, similar to other cardiac glycosides[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neriifolin.